Notice type: 3rd Party Publications
Problem Or Issue:
Important Safety Information communication from Roche Products (Ireland) Ltd. on Tecentriq (atezolizumab): Restriction of indication for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy
Important Safety Information - Tecentriq (atezolizumab)